Extraordinary General Meeting of Active Biotech AB
March 19 2018 - 2:00PM
PRESS RELEASE
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA,
CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE,
DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL.
Extraordinary General Meeting of Active Biotech was
held on March 19, 2018.
The meeting resolved, in
accordance with the board's proposal, on a share issue with
pre-emptive rights for existing shareholders, of approximately SEK
48 million, before issue costs. Through the rights issue, not more
than 48,412,160 new shares are issued. Two existing shares entitle
to subscription for one new share. The rights issue is covered by
subscription commitments and issue guarantee of approximately SEK
30 million, corresponding to approximately 61 percent of the rights
issue.
The subscription price amounts to
SEK 1 per share. The record date for participation in the rights
issue is 26 March 2018. Subscription for the new shares shall be
made during the period 28 March - 11 April 2018. The last day for
trading in the Active Biotech share including the right to
participate in the rights issue is 22 March 2018.
A prospectus regarding the rights
issue will be made public prior to the commencement of the
subscription period.
Lund, March 19, 2018
For further information, please
contact:
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB
(publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with
focus on neurodegenerative/inflammatory diseases and cancer.
Laquinimod, an orally administered small molecule with unique
immunomodulatory properties is in development for neurodegenerative
diseases in partnership with Teva Pharmaceutical Industries Ltd.
ANYARA, an immunotherapy, in development for cancer indications in
partnership with NeoTX Therapeutics Ltd. Furthermore, commercial
activities are conducted for the tasquinimod, paquinimod and SILC
projects. Please visit www.activebiotech.com for more
information.
Active Biotech
AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
IMPORTANT INFORMATION
This press release is not an offer to subscribe for shares in
Active Biotech and investors should not subscribe for or purchase
any securities, except on the basis of information provided in the
prospectus.
This press release may not be made public, released or distributed,
directly or indirectly, in or into the United States, Australia,
Japan or Canada or in any other jurisdiction in which the
distribution of this press release would be unlawful. Further, this
press release does not constitute an offer to sell new shares, paid
subscribed for shares ("BTA") or subscription rights to any person
in any jurisdiction in which it is unlawful to make such offer to
such person or where such action would require additional
prospectuses, registration or other measures other than those
pursuant to Swedish law. The prospectus, application form and other
documents associated with the rights issue may not be distributed
in or to any country where such distribution or the rights issue
would require such measures set forth in the preceding sentence or
be in violation of the regulations of such country.
The new shares, BTAs and subscription rights have not been
recommended or approved by any United States federal or state
securities commission or regulatory authority. No new shares, BTAs,
subscription rights or other securities issued by Active Biotech
have been or will be registered under the U.S. Securities Act of
1933, as amended, or under the securities legislation in any state
of the United States, and may not be offered, exercised or sold in
the United States absent registration or an applicable exemption
from registration requirements. There is no intention to register
any portion of the offering in the United States or to conduct a
public offering of securities in the United States.
The Company has not authorized any offer of the securities referred
to herein to the public in any country in the European Economic
Area ("EEA") other than Sweden. In other member states in the EEA,
the securities may only be offered to (i) any legal entity which is
a qualified investor as defined in the Directive 2003/71/EC (the
"Prospectus Directive"); or (ii) any person falling within Article
3(2) of the Prospectus Directive.
In the United Kingdom, this communication is only being distributed
to, and is only directed at "qualified investors" (as defined in
section 86(7) of the Financial Services and Markets Act 2000) who
are (i) investment professionals falling within the meaning of
Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order"); or (ii) persons
falling within Article 49(2)(a) to (d) ("high net worth companies,
etc.") of the Order (all such persons together being referred to as
"relevant persons"). In the United Kingdom, any investment or
investment activity to which this communication relates is
available only to, and will be engaged in only with, relevant
persons. Any person who is not a relevant person should not take
any action on the basis of this communication and should not act or
rely on it or any of its contents.
This press release may contain forward-looking statements which
reflect Active Biotech's current view on future events and
financial and operational development. Words such as "intend",
"will", "expect", "anticipate", "may", "plan", "estimate" and other
expressions that imply indications or predictions of future
development or trends, constitute forward-looking statements.
Forward-looking statements inherently involve both known and
unknown risks and uncertainties as they depend on future events and
circumstances. Forward-looking statements do not guarantee future
results or development and the actual outcome could differ
materially from the forward-looking statements. The information,
opinions and forward-looking statements included in this press
release speak only as of its date and are subject to change without
notice.
Extraordinary General Meeting of
Active Biotech AB
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From May 2024 to Jun 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Jun 2023 to Jun 2024